BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T, Yamazaki N, Takikawa H, Morimoto T, Chosa M, Sunaya T, Hamada Y, Muro K, Sugihara K. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. Oncologist 2019;24:e450-7. [PMID: 30606885 DOI: 10.1634/theoncologist.2018-0377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Int J Clin Oncol 2020;25:614-21. [PMID: 31838590 DOI: 10.1007/s10147-019-01600-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kobayashi K, Sugiyama E, Shinozaki E, Wakatsuki T, Tajima M, Kidokoro H, Aoyama T, Nakano Y, Kawakami K, Hashimoto K, Suenaga M, Ichimura T, Ogura M, Chin K, Nakayama I, Ooki A, Takahari D, Suzuki W, Yokokawa T, Minowa Y, Hiraoka T, Suzuki K, Sato H, Hama T, Yamaguchi K. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol 2021;87:767-77. [PMID: 33635392 DOI: 10.1007/s00280-021-04237-x] [Reference Citation Analysis]
3 Grothey A, Blay J, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews 2020;86:101993. [DOI: 10.1016/j.ctrv.2020.101993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
4 Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol 2020;12:1758835920956862. [PMID: 33193826 DOI: 10.1177/1758835920956862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu Y, Fan Y, Dong D, Dong X, Hu Y, Shi Y, Jing J, Li E. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. Ther Adv Med Oncol 2020;12:1758835920940932. [PMID: 32728393 DOI: 10.1177/1758835920940932] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Yang Y, Xu L, Wang D, Hui B, Li X, Zhou Y, Chen X, Gu Y. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report. Immunotherapy 2021. [PMID: 34369830 DOI: 10.2217/imt-2020-0327] [Reference Citation Analysis]
7 Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel) 2019;11:E1517. [PMID: 31601010 DOI: 10.3390/cancers11101517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
8 Kawakami K, Wakatsuki T, Soejima A, Kobayashi K, Yokokawa T, Aoyama T, Suzuki K, Suenaga M, Yamaguchi K, Inoue A, Machida Y, Hama T. Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer. Patient Prefer Adherence 2019;13:1745-50. [PMID: 31686792 DOI: 10.2147/PPA.S217835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [DOI: 10.4251/wjgo.v14.i4.920] [Reference Citation Analysis]
10 Hatori M, Kawakami K, Wakatsuki T, Shinozaki E, Kobayashi K, Aoyama T, Nakano Y, Suzuki K, Yamaguchi K, Hama T. Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting. Dose Response 2021;19:15593258211047658. [PMID: 34675759 DOI: 10.1177/15593258211047658] [Reference Citation Analysis]
11 Nakashima M, Ide K, Kawakami K. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study. Target Oncol 2019;14:295-306. [PMID: 31093834 DOI: 10.1007/s11523-019-00642-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 2020;38:172-180. [PMID: 31172442 DOI: 10.1007/s10637-019-00801-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]